Treatment of aplastic anemia with antithymocyte globulin, Lymphoser Berna

S. Kojima, K. Matsumoto, Koji Kato, T. Matsuyama, T. Sugihara, S. Minami, Y. Kodera, Y. Miyajima, I. Katayama, K. Horibe

Research output: Contribution to journalArticle

Abstract

Twenty-four patients with aplastic anemia (19 severe: 5 moderate) were treated with combined immunosuppression consisting of antithymocyte globulin (ATG: Lymphoser Berna, Swiss Serum and Vaccine Institute Berne) and high-dose methylprednisolone. Danazol or meptiostane was administered concurrently for at least 3 months. Three batches of ATG were used, two were not absorbed with thrombocytes and one was absorbed with thrombocytes for the prevention of thrombocytopenia. Nine of 20 evaluable patient (45%) had sustained improvement in hematopoiesis within 3 months of treatment. Nine of 14 patients (64%) showed a response to ATG without thrombocyte absorption, on the other hand, none of 6 patients responded to ATG with thrombocyte absorption. By life table analysis, the 3 year probability of survival was 81 +/- 27% after the combined immunosuppressive therapy. These results indicated that ATG therapy was very effective in Japanese patients with aplastic anemia.

Original languageEnglish
Pages (from-to)815-820
Number of pages6
Journal[Rinshō ketsueki] The Japanese journal of clinical hematology
Volume34
Issue number7
Publication statusPublished - Jan 1 1993
Externally publishedYes

Fingerprint

Antilymphocyte Serum
Aplastic Anemia
Blood Platelets
Danazol
Therapeutics
Life Tables
Hematopoiesis
Methylprednisolone
Immunosuppressive Agents
Thrombocytopenia
Immunosuppression
Vaccines
Survival
Serum

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Kojima, S., Matsumoto, K., Kato, K., Matsuyama, T., Sugihara, T., Minami, S., ... Horibe, K. (1993). Treatment of aplastic anemia with antithymocyte globulin, Lymphoser Berna. [Rinshō ketsueki] The Japanese journal of clinical hematology, 34(7), 815-820.

Treatment of aplastic anemia with antithymocyte globulin, Lymphoser Berna. / Kojima, S.; Matsumoto, K.; Kato, Koji; Matsuyama, T.; Sugihara, T.; Minami, S.; Kodera, Y.; Miyajima, Y.; Katayama, I.; Horibe, K.

In: [Rinshō ketsueki] The Japanese journal of clinical hematology, Vol. 34, No. 7, 01.01.1993, p. 815-820.

Research output: Contribution to journalArticle

Kojima, S, Matsumoto, K, Kato, K, Matsuyama, T, Sugihara, T, Minami, S, Kodera, Y, Miyajima, Y, Katayama, I & Horibe, K 1993, 'Treatment of aplastic anemia with antithymocyte globulin, Lymphoser Berna', [Rinshō ketsueki] The Japanese journal of clinical hematology, vol. 34, no. 7, pp. 815-820.
Kojima, S. ; Matsumoto, K. ; Kato, Koji ; Matsuyama, T. ; Sugihara, T. ; Minami, S. ; Kodera, Y. ; Miyajima, Y. ; Katayama, I. ; Horibe, K. / Treatment of aplastic anemia with antithymocyte globulin, Lymphoser Berna. In: [Rinshō ketsueki] The Japanese journal of clinical hematology. 1993 ; Vol. 34, No. 7. pp. 815-820.
@article{ab2d05afef204580a4757f76cd970850,
title = "Treatment of aplastic anemia with antithymocyte globulin, Lymphoser Berna",
abstract = "Twenty-four patients with aplastic anemia (19 severe: 5 moderate) were treated with combined immunosuppression consisting of antithymocyte globulin (ATG: Lymphoser Berna, Swiss Serum and Vaccine Institute Berne) and high-dose methylprednisolone. Danazol or meptiostane was administered concurrently for at least 3 months. Three batches of ATG were used, two were not absorbed with thrombocytes and one was absorbed with thrombocytes for the prevention of thrombocytopenia. Nine of 20 evaluable patient (45{\%}) had sustained improvement in hematopoiesis within 3 months of treatment. Nine of 14 patients (64{\%}) showed a response to ATG without thrombocyte absorption, on the other hand, none of 6 patients responded to ATG with thrombocyte absorption. By life table analysis, the 3 year probability of survival was 81 +/- 27{\%} after the combined immunosuppressive therapy. These results indicated that ATG therapy was very effective in Japanese patients with aplastic anemia.",
author = "S. Kojima and K. Matsumoto and Koji Kato and T. Matsuyama and T. Sugihara and S. Minami and Y. Kodera and Y. Miyajima and I. Katayama and K. Horibe",
year = "1993",
month = "1",
day = "1",
language = "English",
volume = "34",
pages = "815--820",
journal = "[Rinsho ketsueki] The Japanese journal of clinical hematology",
issn = "0485-1439",
publisher = "Nihon Rinsho Ketsueki Gakkai/Japan Society of Clinical Hematology",
number = "7",

}

TY - JOUR

T1 - Treatment of aplastic anemia with antithymocyte globulin, Lymphoser Berna

AU - Kojima, S.

AU - Matsumoto, K.

AU - Kato, Koji

AU - Matsuyama, T.

AU - Sugihara, T.

AU - Minami, S.

AU - Kodera, Y.

AU - Miyajima, Y.

AU - Katayama, I.

AU - Horibe, K.

PY - 1993/1/1

Y1 - 1993/1/1

N2 - Twenty-four patients with aplastic anemia (19 severe: 5 moderate) were treated with combined immunosuppression consisting of antithymocyte globulin (ATG: Lymphoser Berna, Swiss Serum and Vaccine Institute Berne) and high-dose methylprednisolone. Danazol or meptiostane was administered concurrently for at least 3 months. Three batches of ATG were used, two were not absorbed with thrombocytes and one was absorbed with thrombocytes for the prevention of thrombocytopenia. Nine of 20 evaluable patient (45%) had sustained improvement in hematopoiesis within 3 months of treatment. Nine of 14 patients (64%) showed a response to ATG without thrombocyte absorption, on the other hand, none of 6 patients responded to ATG with thrombocyte absorption. By life table analysis, the 3 year probability of survival was 81 +/- 27% after the combined immunosuppressive therapy. These results indicated that ATG therapy was very effective in Japanese patients with aplastic anemia.

AB - Twenty-four patients with aplastic anemia (19 severe: 5 moderate) were treated with combined immunosuppression consisting of antithymocyte globulin (ATG: Lymphoser Berna, Swiss Serum and Vaccine Institute Berne) and high-dose methylprednisolone. Danazol or meptiostane was administered concurrently for at least 3 months. Three batches of ATG were used, two were not absorbed with thrombocytes and one was absorbed with thrombocytes for the prevention of thrombocytopenia. Nine of 20 evaluable patient (45%) had sustained improvement in hematopoiesis within 3 months of treatment. Nine of 14 patients (64%) showed a response to ATG without thrombocyte absorption, on the other hand, none of 6 patients responded to ATG with thrombocyte absorption. By life table analysis, the 3 year probability of survival was 81 +/- 27% after the combined immunosuppressive therapy. These results indicated that ATG therapy was very effective in Japanese patients with aplastic anemia.

UR - http://www.scopus.com/inward/record.url?scp=0027638322&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027638322&partnerID=8YFLogxK

M3 - Article

C2 - 8360986

AN - SCOPUS:0027638322

VL - 34

SP - 815

EP - 820

JO - [Rinsho ketsueki] The Japanese journal of clinical hematology

JF - [Rinsho ketsueki] The Japanese journal of clinical hematology

SN - 0485-1439

IS - 7

ER -